drugset / Trial / NCT06637072
A Study to Assess Adults With CIDP Transitioning From IVIg to Efgartigimod PH20 SC
NaSingle-groupOpen-labelTreatment
Summary
This study will measure how adults with CIDP receiving IVIg treatment adjust to efgartigimod PH20 SC. The study duration for each participant will be approximately 17 to 19 weeks.
Timeline
- Start
- 2024-12-10
- Primary completion
- 2026-02-19
- Completion
- 2026-02-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Efgartigimod Alfa | Protein / enzyme biologic | — | Subcutaneous |